News coverage about GlaxoSmithKline (NYSE:GSK) has trended positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. GlaxoSmithKline earned a news sentiment score of 2.29 on their scale. InfoTrie also gave media headlines about the pharmaceutical company an news buzz score of 0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted GlaxoSmithKline’s ranking:
- GlaxoSmithKline Teams Up With Mammoth Biosciences on a CRISPR-Based COVID-19 Test (nasdaq.com)
- Research on OTC Drug Market (impact of COVID-19) 2020-2026: GlaxoSmithKline (GSK), Johnson&Johnson, Pfizer – Bandera County Courier (bccourier.com)
- GlaxoSmithKline (NYSE:GSK) Earns Daily News Impact Rating of 2.29 (americanbankingnews.com)
- GSK taps Mammoth Biosciences to develop a CRISPR-based, over-the-counter coronavirus test (fiercebiotech.com)
- S.Korea’s Samsung Biologics signs $231 mln supply deal with GSK (finance.yahoo.com)
GSK has been the topic of a number of recent analyst reports. Shore Capital lowered shares of GlaxoSmithKline from a “hold” rating to a “sell” rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday, May 5th. Barclays reissued an “underweight” rating on shares of GlaxoSmithKline in a report on Thursday, April 30th. UBS Group reissued a “buy” rating on shares of GlaxoSmithKline in a report on Thursday, May 14th. Finally, ValuEngine lowered shares of GlaxoSmithKline from a “hold” rating to a “sell” rating in a report on Friday, May 1st. Four equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. GlaxoSmithKline currently has an average rating of “Hold” and an average price target of $45.00.
The business also recently announced a quarterly dividend, which will be paid on Thursday, July 9th. Stockholders of record on Friday, May 15th will be given a $0.472 dividend. The ex-dividend date is Thursday, May 14th. This represents a $1.89 annualized dividend and a dividend yield of 4.62%. GlaxoSmithKline’s dividend payout ratio is 58.68%.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: Death Cross
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.